XOMA Royalty Says Zevra Therapeutics Received FDA Approval For MIPLYFFA; Says It Is Entitled To Receive Mid-single Digit Royalty On MIPLYFFA Sales And Up To $52.6M In Milestones
Portfolio Pulse from Benzinga Newsdesk
XOMA Royalty announced that Zevra Therapeutics has received FDA approval for MIPLYFFA. XOMA is entitled to receive mid-single digit royalties on MIPLYFFA sales and up to $52.6 million in milestone payments.
September 23, 2024 | 10:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
XOMA Royalty will receive mid-single digit royalties from MIPLYFFA sales and up to $52.6 million in milestone payments following FDA approval.
The FDA approval of MIPLYFFA directly benefits XOMA through royalties and potential milestone payments, likely boosting its revenue and stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 90
POSITIVE IMPACT
Zevra Therapeutics received FDA approval for MIPLYFFA, which is a significant milestone for the company.
FDA approval of MIPLYFFA is a major achievement for Zevra Therapeutics, likely enhancing its market position and stock value.
CONFIDENCE 85
IMPORTANCE 70
RELEVANCE 80